Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by canadafanon Jan 22, 2024 11:01am

206 Views

Post# 35838928

A new day, new week…month almost over

I think this week for a welcome change, both Canadian & Nas markets will have a full trading week.
Looking the Onc world over, brings to light over & over the technical/ clinical/ science opportunities for Pelareorep & Onc as a company.
Matt kicked of the month with an " update".
From that, not much reading required to conclude. He more or less encapsulated what was on the corporate presentation. The PDF of which is still there for the looking.

<< Previous

Bullboard Posts

Next >>

Canadian government approves Glencore’s takeover of Teck’s coal business